医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Introduction of Daily Healthcare and Treatment Effect of Lianhua Qingwen Capsules

2020年12月11日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

Lianhua Qingwen Capsules is a patent innovative traditional Chinese medicine developed by Yiling Pharmaceutical under the guidance of Luobing Theory of traditional Chinese medicine. It is developed by absorbing the valuable experience of traditional Chinese medicine in the treatment of cold and influenza, as well as the research experience drawn from modern anti-virus, antibacterial, and immune enhancement.

Studies have shown that Lianhua Qingwen capsules have the effects of broad-spectrum antiviral, bacteriostatic, antipyretic and antiphlogistic, relieving cough and decreasing sputum, and improving cellular immune function, etc. It can be used to treat influenza that is caused by heat-toxin attacking lungs, whose symptoms include fever, aversion to chills, muscle soreness, nasal congestion, runny nose, cough, headache, dry throat, sore throat, reddish tongue, yellowish tongue or tongue with greasy fur. For regular treatment of the novel coronavirus, Lianhua Qingwen capsules can be used to treat fever, cough and fatigue of lightly and ordinarily infected cases. Lianhua Qingwen Capsules has a wide range of applications. With its crucial role in major public health events and long-term and good reputation among the Chinese people, Lianhua Qingwen Capsules has been listed in recommendations many times by the Chinese authorities for cold and flu, such as the “Commonly Used Medicines by Chinese families in 2019-2020”.

Up to now, Lianhua Qingwen Capsules has obtained approval certificates from nearly 20 countries, including Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos, and has officially entered the Philippine market on November 23. Currently, the Philippine consumers can buy the medicine at the South Star Drug, Watsons and Mercury Drug.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005280/en/

CONTACT

First Name: Li

Last Name: Kristy

E-mail:kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单
  • Aceto Expands Life Science Manufacturing with Acquisition of Finar Limited